Use of ferumoxides for stem cell labeling

Hesham Sadek, Shuaib Latif, Robert Collins, Mary G. Garry, Daniel J. Garry

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: Although numerous clinical trials have shown promising results with regards to the cardiac regenerative capacity of different types of stem cells, there remains virtually no evidence of the fate of stem cells in these human studies, primarily owing to safety concerns associated with the use of cell-labeling strategies. Methods: In this study, we utilized two cell types that are used extensively in cardiac regeneration studies, namely bone marrow-derived human mononuclear cells and C2C12 skeletal myoblasts. The US FDA-approved compounds feridex (ferumoxide) and protamine sulfate (as a transfection agent) were used in combination for cellular labeling. We assessed the effect of this cell labeling strategy on cellular viability, proliferation and differentiation both in vitro and in vivo. Results: The ferumoxide-protamine sulfate combination had no effect on cellular viability, proliferation or differentiation. We show that the labeled human mononuclear cells were easily identified within the rat myocardium 1 month following injection into the myocardium. These human cells expressed human-specific cardiac troponin I, whereas the neighboring rat myocardium did not. Furthermore, we demonstrated that this labeling strategy can be used with high accuracy for magnetic separation of the labeled cells based on the intracellular ferumoxide particles. Conclusions: The ferumoxide-protamine sulfate combination can be used safely and effectively to enhance the detection and isolation of cardiogenic stem cell populations.

Original languageEnglish (US)
Pages (from-to)807-816
Number of pages10
JournalRegenerative Medicine
Volume3
Issue number6
DOIs
StatePublished - 2008

Fingerprint

Stem cells
Labeling
Stem Cells
Protamines
Rats
Myocardium
Magnetic separation
Cell Proliferation
Skeletal Myoblasts
Bone
Troponin I
Cell Separation
Cells
Transfection
ferumoxides
Regeneration
Bone Marrow
Clinical Trials
Safety
Sulfates

Keywords

  • Cardiomyocytes
  • Cell-transfer therapies
  • Ferumoxides
  • Heart
  • Human stem cells
  • Stem cells

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

Use of ferumoxides for stem cell labeling. / Sadek, Hesham; Latif, Shuaib; Collins, Robert; Garry, Mary G.; Garry, Daniel J.

In: Regenerative Medicine, Vol. 3, No. 6, 2008, p. 807-816.

Research output: Contribution to journalArticle

Sadek, Hesham ; Latif, Shuaib ; Collins, Robert ; Garry, Mary G. ; Garry, Daniel J. / Use of ferumoxides for stem cell labeling. In: Regenerative Medicine. 2008 ; Vol. 3, No. 6. pp. 807-816.
@article{68549695cce244ac9b23c3f568a8c972,
title = "Use of ferumoxides for stem cell labeling",
abstract = "Aim: Although numerous clinical trials have shown promising results with regards to the cardiac regenerative capacity of different types of stem cells, there remains virtually no evidence of the fate of stem cells in these human studies, primarily owing to safety concerns associated with the use of cell-labeling strategies. Methods: In this study, we utilized two cell types that are used extensively in cardiac regeneration studies, namely bone marrow-derived human mononuclear cells and C2C12 skeletal myoblasts. The US FDA-approved compounds feridex (ferumoxide) and protamine sulfate (as a transfection agent) were used in combination for cellular labeling. We assessed the effect of this cell labeling strategy on cellular viability, proliferation and differentiation both in vitro and in vivo. Results: The ferumoxide-protamine sulfate combination had no effect on cellular viability, proliferation or differentiation. We show that the labeled human mononuclear cells were easily identified within the rat myocardium 1 month following injection into the myocardium. These human cells expressed human-specific cardiac troponin I, whereas the neighboring rat myocardium did not. Furthermore, we demonstrated that this labeling strategy can be used with high accuracy for magnetic separation of the labeled cells based on the intracellular ferumoxide particles. Conclusions: The ferumoxide-protamine sulfate combination can be used safely and effectively to enhance the detection and isolation of cardiogenic stem cell populations.",
keywords = "Cardiomyocytes, Cell-transfer therapies, Ferumoxides, Heart, Human stem cells, Stem cells",
author = "Hesham Sadek and Shuaib Latif and Robert Collins and Garry, {Mary G.} and Garry, {Daniel J.}",
year = "2008",
doi = "10.2217/17460751.3.6.807",
language = "English (US)",
volume = "3",
pages = "807--816",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Use of ferumoxides for stem cell labeling

AU - Sadek, Hesham

AU - Latif, Shuaib

AU - Collins, Robert

AU - Garry, Mary G.

AU - Garry, Daniel J.

PY - 2008

Y1 - 2008

N2 - Aim: Although numerous clinical trials have shown promising results with regards to the cardiac regenerative capacity of different types of stem cells, there remains virtually no evidence of the fate of stem cells in these human studies, primarily owing to safety concerns associated with the use of cell-labeling strategies. Methods: In this study, we utilized two cell types that are used extensively in cardiac regeneration studies, namely bone marrow-derived human mononuclear cells and C2C12 skeletal myoblasts. The US FDA-approved compounds feridex (ferumoxide) and protamine sulfate (as a transfection agent) were used in combination for cellular labeling. We assessed the effect of this cell labeling strategy on cellular viability, proliferation and differentiation both in vitro and in vivo. Results: The ferumoxide-protamine sulfate combination had no effect on cellular viability, proliferation or differentiation. We show that the labeled human mononuclear cells were easily identified within the rat myocardium 1 month following injection into the myocardium. These human cells expressed human-specific cardiac troponin I, whereas the neighboring rat myocardium did not. Furthermore, we demonstrated that this labeling strategy can be used with high accuracy for magnetic separation of the labeled cells based on the intracellular ferumoxide particles. Conclusions: The ferumoxide-protamine sulfate combination can be used safely and effectively to enhance the detection and isolation of cardiogenic stem cell populations.

AB - Aim: Although numerous clinical trials have shown promising results with regards to the cardiac regenerative capacity of different types of stem cells, there remains virtually no evidence of the fate of stem cells in these human studies, primarily owing to safety concerns associated with the use of cell-labeling strategies. Methods: In this study, we utilized two cell types that are used extensively in cardiac regeneration studies, namely bone marrow-derived human mononuclear cells and C2C12 skeletal myoblasts. The US FDA-approved compounds feridex (ferumoxide) and protamine sulfate (as a transfection agent) were used in combination for cellular labeling. We assessed the effect of this cell labeling strategy on cellular viability, proliferation and differentiation both in vitro and in vivo. Results: The ferumoxide-protamine sulfate combination had no effect on cellular viability, proliferation or differentiation. We show that the labeled human mononuclear cells were easily identified within the rat myocardium 1 month following injection into the myocardium. These human cells expressed human-specific cardiac troponin I, whereas the neighboring rat myocardium did not. Furthermore, we demonstrated that this labeling strategy can be used with high accuracy for magnetic separation of the labeled cells based on the intracellular ferumoxide particles. Conclusions: The ferumoxide-protamine sulfate combination can be used safely and effectively to enhance the detection and isolation of cardiogenic stem cell populations.

KW - Cardiomyocytes

KW - Cell-transfer therapies

KW - Ferumoxides

KW - Heart

KW - Human stem cells

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=58149119399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149119399&partnerID=8YFLogxK

U2 - 10.2217/17460751.3.6.807

DO - 10.2217/17460751.3.6.807

M3 - Article

C2 - 18947305

AN - SCOPUS:58149119399

VL - 3

SP - 807

EP - 816

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 6

ER -